Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study - Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022919

Enrollment

122

Registered

2016-07-01

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients who required continuous renal replacement therapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult critically ill patients who required continuous renal replacement therapy in our intensive care unit from January 2011 to December 2013.

Exclusion criteria

Exclusion criteria: Patients who required additional extracorporeal intervention including extracorporeal membrane oxygenation or intra-aortic balloon pumping. Patients who were administered other anticoagulants including unfractionated heparin and gabexate mesilate.

Design outcomes

Primary

Measure	Time frame
the incidence of bleeding complications	—

Countries

Japan

Contacts

Public ContactShohei Makino

Kobe University Hospital Anesthesiology

timasuke555@yahoo.co.jp0783826172

Outcome results